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ABSTRACT 
Background: Primary percutaneous coronary intervention (PPCI) is the default treatment for 
patients with ST elevation myocardial infarction (STEMI) and carries a higher risk of adverse 
outcomes when compared with elective and urgent PCI. Conventional PCI risk scores tend to 
be complex and may underestimate the risk associated with PPCI due to under-
representation of patients with STEMI in their datasets. This study aimed to develop a 
simple, practical and contemporary risk model to provide risk stratification in PPCI. 
Methods: Demographic, clinical and outcome data were collected for all patients who 
underwent PPCI between January 2009 and October 2013 at the Northern General Hospital, 
Sheffield. Multiple regression analysis was used to identify independent predictors of 
mortality and to construct a risk model. This model was then separately validated on an 
internal and external dataset. 
Results: The derivation cohort included 2,870 patients with a 30-day mortality of 5.1% (145 
patients).  Only four variables were required to predict 30-day mortality: age [OR:1.047, 95% 
CI:1.031-1.063], call-to-balloon (CTB) time [OR:1.829, 95% CI:1.198-2.791], cardiogenic shock 
[OR:13.886, 95% CI:8.284-23.275] and congestive heart failure [OR:3.169, 95% CI:1.420-
7.072]. Internal validation was performed in 693 patients and external validation in 660 
patients undergoing PPCI. Our model showed excellent discrimination on ROC-curve analysis 
(C-Stat = 0.87 internal and 0.86, external), and excellent calibration on Hosmer-Lemeshow 
testing (p=0.37 internal, 0.55 external). 
Conclusions: We have developed a bedside risk model which can predict 30-day mortality 
after PPCI using only four variables: age, CTB time, congestive heart failure and shock. 
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Background 
Primary percutaneous coronary intervention (PPCI) is the preferred revascularisation 
treatment for ST-elevation myocardial infarction (STEMI)[1, 2]. Compared with PCI for 
elective and urgent PCI, PPCI carries a higher risk of adverse outcomes [3]. Early 
identification of these risks and their likely effect on patient outcomes enables care to be 
tailored to the individual. Under-use of risk scores is common due to their complexity, and 
inclusion of variables that are not readily available at the bedside in an emergency situation. 
Conventional PCI risk scores may underestimate the risk associated with PPCI due to under-
representation of patients with STEMI in their datasets [3-9]. urrently there are very few 
dedicated PPCI risk scores and many are based on outdated data [10-12]. A recent model 
aimed at PPCI, excluded many high-risk but low-incidence variables such as shock, limiting its 
ability to identify the highest risk patients [13]. Other studies have included many variables, 
but few are immediately available when a patient presents with STEMI [14, 15], limiting their 
use in the acute setting. This study therefore aimed to develop a simple and practical risk 
model from contemporary data to provide risk stratification in the emergency room or 
ambulance before PPCI is undertaken. 
 
METHODS 
We constructed a PPCI risk score by examining the procedural and clinical database of the 
Northern General Hospital Sheffield, a tertiary interventional Cardiology centre providing 
PPCI services for a population of 1.8 million people in the north of England.  This centre 
performs approximately 700 PPCI per annum.  We examined the records of all patients who 
underwent PPCI between January 2009 and October 2013. In Sheffield risk data is currently 
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gathered via the New York Risk Score, we tested the calibration and discrimination of this 
model on our data using Hosmer-Lemeshow testing and ROC-curve analysis respectively.  
In order to create our risk model only variables that are readily available at the bedside pre-
PCI were included in the analysis. For each patient we gathered information on age, sex, 
 ?ĐĂůů-to-ďĂůůŽŽŶ ? ?d ?ƚŝŵĞ ?ŚĂĞŵŽĚǇŶĂŵŝĐƐƚĂƚĞ ?ĐĂƌĚŝŽŐĞŶŝĐƐŚŽĐŬ ? ?ƉƌĞǀŝŽƵƐD/ ?ĚŝĂďĞƚĞƐ ?
smoking status, a prior cerebrovascular event, significant valvular heart disease, 
hypercholesterolemia, hypertension, peripheral vascular disease, congestive cardiac failure 
and renal failure (see appendix for definitions). Age was analysed as both continuous and 
binary with different thresholds for binary split analysed. The primary outcome was 30-day 
mortality. Univariate logistic regression was used to assess the effect of each variable upon 
30-day mortality. A threshold of p<0.05 was used for entry into multivariate analysis. 
Significant univariate predictors of 30-day mortality were then entered into a backward 
ƐƚĞƉǁŝƐĞůŽŐŝƐƚŝĐƌĞŐƌĞƐƐŝŽŶǁŝƚŚƉA? ? ? ? ?ĂƐƚŚĞƚŚƌĞƐ ŽůĚĨŽƌĞŶƚƌǇŝŶƚŽƚŚĞĨŝŶĂůŵŽĚĞů ?dŽ
ĂǀŽŝĚ ?ĐŽŵƉůĞƚĞĐĂƐĞ ?ďŝĂƐ ?ǁĞƵƐĞĚmultiple imputation, in which missing data are replaced 
with substituted values, whilst accounting for uncertainty by creating multiple plausible 
estimates [16, 17].  Internal validation was performed on patients undergoing PPCI in 
Sheffield between November 2013 and October 2014.  External validation was performed on 
a cohort of PPCI patients from Manchester Royal Infirmary who had been treated between 
2012 and 2014. Discrimination of the model was determined with ROC-curve analysis [18]. 
Calibration of the model was measured by the Hosmer-Lemeshow test.  A P-value of <0.05 
indicated statistical significance. 
 
RESULTS 
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2564 patients had sufficient data to calculate a risk probability using the New York risk 
model.  132 (5.14%) of these patients were dead at 30-days. The New York risk score 
produced a C-statistic of 0.847 under ROC-curve analysis indicating excellent discrimination. 
The ROC-curve can be seen in Figure 1a. However Hosmer-Lemeshow testing indicated that 
there was a significant difference between the predicted and observed values (p=0.003). 
The derivation cohort included 2,870 patients who underwent PPCI at Sheffield. Of these, 
 145 (5.1%) patients had died by 30 days. The average age of the patients that died 
was 69 years vs 61 for the survivors. Age was split into A? ? ?ǀƐA? ? ?ǇĞĂƌƐ with mortality rates 
of 3.6% vs 9.2% respectively. Variables with a significant univariate relationship with 30-day 
mortality included age, CTB time, shock, congestive heart failure, peripheral arterial disease, 
renal failure, prior cerebrovascular accident, and sex (Table 1). Following multivariate logistic 
regression analysis, four variables were found to be significant; age (P<0.001, OR: 1.047, CI: 
1.031-1.063), CTB time (P=0.005, OR: 1.829, CI: 1.198-2.791), shock (P<0.001, OR: 13.886, CI: 
8.284-23.275) and congestive heart failure (P=0.006, OR: 3.169, CI: 1.420-7.072) (Table 2).  
The results of this analysis were used to create the following equation for the probability ሺ݌ሻ 
of a patient dying. 
݌ ൌ ݁ሺ଴Ǥ଴ସ଺࡭ା଴Ǥ଺଴ସ࡮ାଶǤ଺ଷଵ࡯ାଵǤଵହଷࡰି଺Ǥହ଼ଶሻሺ ? ൅ ሺ݁଴Ǥ଴ସ଺࡭ା଴Ǥ଺଴ସ࡮ାଶǤ଺ଷଵ࡯ାଵǤଵହଷࡰି଺Ǥହ଼ଶሻሻ 
Where A = age, B = CTB time, C = shock, and D = congestive heart failure.  
When applying this equation to the original dataset, 2491 patients had sufficient data to 
calculate a probability. 2328 (93%) patients had predicted risks of between 0 and 10% and 36 
(1.4%) had a predicted risk above 50%. Hosmer-Lemeshow test indicated that there was no 
significant difference between the observed and predicted number of deaths (p=0.66). ROC-
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curve analysis produced a C-statistic of 0.839 indicating excellent discrimination (Figure 1b). 
A user friendly version app has been created to facilitate the use of this risk score.[19] 
 
Internal Validation 
The model was internally validated on patients who underwent PPCI in Sheffield between 
November 2013 and October 2014. In total 693 patients underwent PPCI during this period 
and of these 44 (6.3%) died. The mean age of these patients was 62 years, and the mean age 
of survivors vs those who died was 61 vs 72 years. Twenty five patients had cardiogenic 
shock, and of these 12 (48%) died; 10 had congestive heart failure and of these 4 (40%) died; 
ĂŶĚ ? ? ?ŚĂĚĂdƚŝŵĞA? ?Ś ?ĂŶĚŽĨƚŚĞƐĞ ? ? ? ? ? ?A? ?ĚŝĞĚ   ?ƉĂƚŝĞŶƚƐŚĂĚƐƵĨĨŝĐŝĞŶƚĚĂƚĂƚŽ
calculate a risk probability, and of these 569 (93%) patients had a predicted risk 0-10% and 4 
(0.8%) had a predicted risk >50%. ROC-Curve analysis yielded a C-statistic of 0.87 indicating 
excellent discrimination (Figure 1c), and Hosmer-Lemeshow testing was insignificant 
(P=0.37) indicating no significant difference between the number of predicted and observed 
deaths. 
 
External Validation 
Data were collected from 1474 patients who underwent PPCI between January 2012 and 
December 2014 at Manchester Royal Infirmary. In total 100 patients died by 30 days (6.7%). 
Their average age was 61, and the mean age of survivors vs those who died was 60 vs 70 
years.  74 patients had cardiogenic shock, and of these 32 (43.2%) died; 274 patients had CTB 
ƚŝŵĞA? ?Ś ?ĂŶĚŽĨƚŚĞƐĞ ? ? ? ? ? ? ?A? ? ?ĂŶĚ ? ? ?ƉĂƚŝĞŶƚƐŚĂĚ ĐŽŶŐĞƐƚŝǀĞŚĞĂƌƚĨĂŝůƵƌĞ ?ŽĨǁŚŝĐŚ ? ?
(26.7%) died.  660 patients had data sufficient to calculate a risk probability, and of these 
591 (90%) had a predicted risk 0-10%, and 21 (3.1%) a predicted risk >50%. The model was 
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shown to have excellent discrimination (C-statistic = 0.86) on ROC-curve analysis (Figure 1d), 
and excellent calibration on Hosmer-Lemeshow test (p=0.55) indicating no significant 
difference between predicted and observed values. 
  
DISCUSSION 
We have developed and validated a simple, practical, dedicated risk score for patients 
undergoing PPCI for STEMI.  This score included four variables; age, CTB time, cardiogenic 
shock and congestive heart failure; these being clinical variables commonly available in the 
acute setting without the need to wait for the results of laboratory tests or the coronary 
angiogram. 
 
Our study used a similar sample size (2870) to previous studies (1791 to 3252), has a similar 
mean patient age (62 years vs 59-61 in the CADILLAC, RISK PPCI, ZWOLLE and PAMI risk 
scores) [10-13] and a similar proportion of females (27% vs 27% in the CADILLAC, RISK PPCI, 
and PAMI risk studies). The Sheffield 30-day mortality rate was considerably higher than that 
of the older PPCI risk scores (5.1% vs 2.1% and 3.6% in the Cadillac, and Zwolle studies, 
respectively). It had a similar mortality rate to the RISK-PCI (2013) score (4.9%) and a lower 
mortality than the more contemporary validation sets (6.3% and 6.7% for the Sheffield, 
2013-14, and Manchester, 2012-14, datasets respectively). This may be due to operators 
offering treatment to a wider range of patients, a lower threshold for PPCI in recent times, or 
a difference in demographics. The UK PCI mortality has steadily risen over the last decade, 
from 0.92% in 2007 to 1.9% in 2015 [20], a trend largely explained by the rapid expansion of 
PPCI in the UK in that era.  
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Age is an important predictor of mortality in many interventions, and particularly coronary 
interventions [21]. In our study the average age of those who died was 69 vs 61 for those 
who survived. Elderly patients represent a high risk group for adverse events in peri-
procedural phase [22]. These patients can potentially be frail and have more comorbidities, 
which can lead to poor outcomes [23]. Indeed, in our cohort, patients over the age of 70 
were more likely to have peripheral arterial disease (5.8% vs 18.3%), cerebrovascular event 
(1.7% vs 4.5%) and renal disease (0.6% vs 2.4%) than those under the age of 70 years.  
 
Delays to treatment are of importance in STEMI [22, 23]. Although not known precisely at 
the time of presentation, we therefore also studied call-to-balloon (CTB) time, and divided 
them into CTBAM ?ŚǀƐA? ?Ś. There was no significant difference in age (62 vs 63 years), but a 
significantly higher rate of cardiogenic shock (4.4% vs 8.3%, P=<0.001), peripheral arterial 
disease (8.3% vs 11.3%, P=0.040) and congestive heart failure (1.6% vs 3.7%, P=0.003). .  
 
Cardiogenic shock was the strongest predictor of 30-day mortality, albeit with a large 
confidence interval (9.1  ? 24.1), probably because only 138 (4.8%) patients out of 2869 had 
this condition. Patients with shock were four years older than those without (66 vs 62 years) 
and were more likely to suffer from congestive heart failure (23.7 vs 1.0%, P=<0.001) and 
peripheral arterial disease (16.7% vs 8.6%, P=0.002).  Shock is a major risk factor in PCI [24] 
and has been included in many of the major risk scores [3, 6, 9, 11, 12]. Congestive heart 
failure conferred a 3-fold higher risk of 30-day mortality than for patients without this 
condition. Patients with congestive heart failure were 7 years older than those without (69 
vs 62 years) and more likely to suffer from peripheral arterial disease (23.6% vs 8,6%, 
P=<0.001). Congestive heart failure features in many risk scores [4, 5, 10-12], but there is 
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marked variation in how it is stratified. Many risk scores use either Killip or NYHA class to 
stratify heart failure [3, 6, 10-12]. In order to maximise sensitivity and simplify the process, 
we decided to include CHF as categorical variable (present or absent). 
 
A simple and accurate bedside risk score for STEMI would be useful for early risk 
stratification. It would inform the judgment of a PCI operator, enabling them to more 
adequately prepare for a complex or hazardous procedure and contribute to the awareness 
of the risks by emergency department staff and cardiac catheterization laboratory staff. Early 
risk stratification also provides the patient and family with a fair indication of what might 
occur. In the most high risk cases, a judgment has to be made as to whether to undertake a 
procedure at all, and a numerical risk score can help contribute to that difficult decision. 
In addition, the score could, more accurately than currently available scores, allow for risk 
adjustment to published individual operator outcomes and help avoid risk adverse 
behaviour. 
 
Limitations 
The main limitation of the study is the relatively modest sample size derived from a single 
PPCI centre. This may have the consequence that infrequent but important conditions such 
as cancer may be under-represented. The advantage of a single centre approach is that the 
data are consistent.  Another weakness of this analysis is inter-observer variability, such as 
precisely defining cardiogenic shock. In addition, some important variables were deliberately 
excluded, because of their not being immediately available, such as creatinine level or left 
ventricular ejection fraction.  Also, CTB time is not strictly speaking a pre-procedural variable, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Page 10 of 17 
 
but it can be estimated with fair precision at the time of arrival of the patient (at least an 
estimate of > or <3h, as studied here.) 
 
Conclusion 
We have successfully created a bedside risk model which can predict 30-day mortality after 
primary PCI which has performed favourably at both internal and external validation. The 
model contains only four variables; age, CTB time, congestive heart failure and shock, all of 
which are available prior to PCI. This model can be used in a clinical setting. The model will 
need to be recalibrated from time to time, and in a larger cohort. 
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Appendix 
1 ± Definitions 
1.1 - Call to balloon time 
This is the length of time elapsed between the patient calling for professional help and PCI.  
1.2 - Shock 
This was defined as blood pressure <90mmHg (or maintained by balloon pump/inotropes) 
with signs of hypoperfusion, e.g. impaired consciousness, oliguria, peripheral cyanosis and 
cold skin.  
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1.3 - History of renal disease 
This was defined as a serum creatinine >200µmol/l, or dialysis dependence, or the presence of 
a functioning transplanted kidney. 
1.4 ± Diabetes  
This refers to both Type 1 and Type 2 diabetes regardless of treatment regime.  
1.5 ± Previous MI 
This is defined as any myocardial infarction which has occurred prior to the current period of 
care.  
1.6 - New York Risk Score Definitions  
All of the following definitions are quoted from the appendix of the paper for the New York 
risk score. 4 
1.6.1 ± Haemodynamic state 
Unstable patients were defined as those requiring mechanical or pharmacological support to 
maintain blood pressure or cardiac output. Patients in cardiogenic shock were defined as 
suffering from acute hypotension (systolic BP <80mmHg) or low cardiac index (<2.0 L/min2) 
despite pharmacological or mechanical support. 
1.6.2 ± LV ejection fraction 
This was the value of ejection fraction (as a percentage) taken closest to PCI. Missing values 
ZHUHFRPELQHGZLWKWKHJURXSDQGZHUHWUHDWHGDVWKHUHIHUHQFHJURXSLQWKLVVWXG\ 
thrombus in the stented segment of the artery or adjacent area following a previous PCI. 
1.6.3 ± Peripheral arterial disease 
7KLVZDVGHILQHGDVDQJLRJUDSKLFHYLGHQFHRIVWHQRVLVLQDPDMRUDRUWRLOLDFRU
femoral/popliteal vessel, previous surgery for this disease, absent femoral or pedal pulses or 
the inability to insert a catheter/intra-aortic balloon due to an iliac aneurysm or obstruction of 
the aortoiliac or femoral arteries. 
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1.6.4 ± Congestive heart failure 
CHF was diagnosed by the presence of one of the following: paroxysmal nocturnal dyspnoea, 
dyspnoea on exertion due to heart failure, or crackles or rales on the lungs.  
1.6.5 ± Left main stem disease 
7KHSDWLHQWKDVDQJLRJUDSKLFHYLGHQFHRIVWHQRVLVLn the left main coronary artery.  
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Table 1 ± Summary Statistics and univariate analysis results 
Continuous Variables Overall (±SD) 
Alive @ 30  
days (±SD) 
Dead @30 
days (±SD) P-Value 
Odds 
ratio 
Confidence 
interval  
Lower Upper 
Average Age 62 (±12) 61 (±12) 69 (±12) <0.001 1.053 1.038 1.068 
Discrete Variables 
Non-imputed Pooled Imputer data 
Count Mortality % Count 
Mortality 
% P-Value 
Odds 
Ratio 
Confidence 
Interval 
Lower Upper 
Congestive 
Heart Failure 
No 2546 4.2 16580 4.3 
<0.001 15.917 9.012 28.113 
Yes 55 41.8 371 41 
Call to Balloon 
Time 
<3hrs 2221 3.8 13795 4.0 
<0.001 2.36 1.622 3.435 
KUV 530 8.5 3306 9.1 
Shock 
No 2731 3.1 16058 3.1 
<0.001 20.611 13.687 31.039 
Yes 138 39.9 902 39.4 
Peripheral 
Arterial Disease 
tab 2360 4.4 15379 4.3 
<0.001 3.207 2.084 4.935 
Yes 235 12.8 1566 12.5 
Hx of Renal 
Disease 
No 2837 4.9 17036 4.9 
0.001 4.853 1.952 12.064 
Yes 30 20 181 19.9 
Cerebrovascular 
Accident 
No 2800 4.9 16800 4.9 
0.004 2.89 1.406 5.942 
Yes 70 12.9 420 12.9 
Gender 
Male 2103 4.5 12618 4.5 
0.031 1.474 1.036 2.098 
Female 767 6.5 4602 6.5 
Previous MI 
No 2308 4.8 14322 5.0 
0.89 0.938 0.576 1.528 
Yes 446 4.5 2782 4.9 
Diabetes 
No 2434 4.5 15058 4.8 
0.106 1.548 0.972 2.463 
Yes 337 6.8 2063 6.9 
Hypercholestero
laemia 
Non 
Known 1839 5.5 11034 5.5 0.152 0.767 0.534 1.102 
Yes 1031 4.3 6186 4.3 
Hypertension 
Non 
Known 1965 5.3 11790 5.3 0.387 0.849 0.586 1.230 
Yes 905 4.5 5430 4.5 
Smoking Status 
Non 
Smoker 605 4.5 4979 5.9 -- -- -- -- 
Previous 535 4.5 4271 5.9 0.967 1.005 0.573 1.765 
Current 981 2.8 7221 3.6 0.051 0.606 0.352 1.043 
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Table 2 - Results of backward stepwise logistic regression on imputed 
data 
Variable Odds Ratio 
95% Confidence interval 
P-value 
Lower Upper 
AGE (<70,  1.047 1.031 1.063 <0.001 
CTB Time 1.829 1.198 2.791 0.005 
Shock 13.886 8.284 23.275 <0.001 
CHF 3.169 1.42 7.072 0.006 
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Highlights 
x Current PCI risk models are complex and there is a lack of contemporary risk models 
specifically for STEMI patients undergoing Primary PCI. 
x We have created a simple and effective risk model to predict 30-day mortality 
following a STEMI. We use only 4 readily available bedside variables; Age, Call to 
Balloon time, Congestive heart failure and Shock. 
x Our model has performed favourably in both internal and external validation 
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